AHA Coding Clinic® for HCPCS - 2018 Issue 2; For Your Information
Deletion of biosimilar modifiers
The biosimilar modifiers ZA, ZB, and ZC were created to distinguish between biosimilar products that appeared in the same HCPCS code but made by different manufacturers. However, with the establishment of new HCPCS codes Q5103 and Q5104, modifiers ZA, ZB, and ZC are no longer necessary and were discontinued as of April 1, 2018. ...
Subscribe or sign in to view the full article.
Article Overview
This article covers a HCPCS Level II update involving biosimilar modifiers and the transition to newer product codes. It is relevant to coding professionals, billing staff, and reimbursement teams who need to track code-set changes and understand which identifiers were discontinued and when. The discussion focuses on the background for the change, the affected modifiers, the associated HCPCS codes, and the effective date of the update.
Why This Topic Matters
Keeping current with HCPCS updates helps prevent use of outdated identifiers and supports accurate billing and claims processing for biosimilar products.
What You Will Learn
- Why certain biosimilar-related modifiers were discontinued
- How newer HCPCS product codes affected the need for the modifiers
- When the change took effect
- Which HCPCS identifiers are involved in the update
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance teams
- Healthcare administrators
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com